Participated · Series B · Apr 2026

Sepion Technologies develops ultra-thin, drop-in polymer separator coatings and membrane technologies intended to replace legacy ceramic materials in lithium-ion batteries. Its coatings aim to enable higher energy density, faster charging, and improved durability without requiring changes to existing battery manufacturing lines. The company reports its products are currently being manufactured on commercial production lines to support customer qualification with leading global battery manufacturers. Sepion is supporting multiple concurrent qualification programs for electric vehicle, energy storage system, and consumer electronics applications. Led by CEO Peter Frischmann and based in Alameda, CA, the company plans to use recent funding to scale U.S.-based polymer production, expand product lines, and strengthen quality and operations.

Participated · Equity · Sep 2024

Invizius is an Edinburgh-based biotech developing H-Guard, a surface-coating therapy flushed through dialysis machines to reduce the inflammatory response when patients' blood contacts machine surfaces. H-Guard aims to prevent immune reactions that can cause organ and cardiovascular damage in dialysis patients. A 'First in Human' study earlier this year demonstrated safety, tolerability and produced encouraging biomarker data. The new funding will support preparation for the next stage of clinical trials and the design of a trial for continuous renal replacement therapy (CRRT) to assess immune modulation and reduction of renal tubule damage. The company plans to advance into Phase 2B trials and continue research into additional patient benefits for H-Guard. Financially, the latest raise brings Invizius's total capital raised to over £13m. Invizius, based in Motherwell, Scotland, is a University of Edinburgh spin-out founded in 2017 and led by CEO Richard Boyd. The company is developing proprietary H-Guard® Priming Solution, a novel protein that lines the inside of the dialysis filter to prevent the blood’s foreign body response. Its core product aims to suppress unwanted innate immune responses and reduce the life-threatening inflammatory effects of haemodialysis. Invizius has established the regulatory pathway in North America and sees potential for coincident approval in Europe. The company intends to use the Series A funds to complete a First-in-Man safety study in 2022. It is also looking to expand its product pipeline into other high-value indications. Invizius is a University of Edinburgh spinout advancing dialysis technology to reduce cardiovascular risk in long-term dialysis patients. Its lead product, H-Guard™, is an anti-inflammatory 'primer' designed to coat filter surfaces so that when mixed with a patient's blood the surface appears less foreign to the immune system. The company plans to use the recent funds to build its team and advance the product toward the next stage of development ahead of clinical trials. The technology was developed from years of research by biologist Dr Andy Herbert (CTO) and his team, and the company is led by CEO Richard Boyd. Although the first application targets kidney dialysis, Invizius sees potential to apply the coating to other devices and procedures such as catheters, stents, organ transplants and vascular grafts. Invizius secured £500k from Mercia Fund Managers in the company's latest financing; the investment followed Mercia's partnership with the University of Edinburgh announced in November 2017.

Participated · Series A · Jun 2024

iCOMAT’s core product is its Rapid Tow Shearing (RTS) process, an automated manufacturing technique that rearranges carbon-fibre tows so components are both lighter and stronger than those made with conventional composite lay-up. The company has just opened the 45,000 sq ft Advanced Composites Manufacturing Enterprise (ACMA) in Hardwicke, Gloucester, equipped with separate 2D-RTS and 3D-RTS production lines for satellite panels, solar-array substrates and curved propellant tanks. By reducing material usage, RTS lowers weight and cost while improving sustainability—critical benefits for spacecraft and satellites. The plant operates on an open-access model, allowing customers and research partners to prototype or scale production with RTS technology. Although designed for space, the same processes can be applied to next-generation aerospace and automotive parts, broadening iCOMAT’s commercial scope. The facility is projected to catalyse 2,000 skilled jobs and anchor a domestic supply chain for advanced composites in the UK. Development of ACMA was financed through a blend of public grants and match funding, underscoring strong institutional support but the article does not disclose any revenue or user metrics for the company.

Participated · Equity · Jan 2013

Bioeutectics produces green solvents built on Natural Deep Eutectic Solvents (NADES) that mimic the way plants elaborate their own solvents. Its formulations use 100% renewable sources to replace petrochemical-based solvents. The company says its solvents offer improved environmental, health, and safety profiles and contribute to sustainable development goals. Syensqo Ventures participated in a $2.1 million financing round for Bioeutectics, strengthening an existing partnership with the Genesis Consortium and support from SOSV’s IndieBio program. The investment aligns with Syensqo’s Renewable Materials and Biotechnology growth platform and its commitment to developing more sustainable solutions across food, agro, industrial and biopharma sectors.